Management of acute asthma exacerbations. Stenson, E. K., Tchou, M. J., & Wheeler, D. S. Curr Opin Pediatr, 29(3):305–310, 1, 2017.
Management of acute asthma exacerbations [link]Paper  doi  abstract   bibtex   
PURPOSE OF REVIEW: Herein, we review the current guidelines for the management of children with an acute asthma exacerbation. We focus on management in the emergency department, inpatient, and ICU settings. RECENT FINDINGS: The most recent statistics show that the prevalence of asthma during childhood has decreased in certain demographic subgroups and plateaued in other subgroups. However, acute asthma accounts for significant healthcare expenditures. Although there are few, if any, newer therapeutic agents available for management of acute asthma exacerbations, several reports leveraging quality improvement science have shown significant reductions in costs of care as well as improvements in outcome. SUMMARY: Asthma is one of the most common chronic conditions in children and the most common reason that children are admitted to the hospital. Nevertheless, the evidence to support specific agents in the management of acute asthma exacerbations is surprisingly limited. The management of acute exacerbations focuses on reversal of bronchospasm, correction of hypoxia, and prevention of relapse and recurrence. Second-tier and third-tier agents are infrequently used outside of the ICU setting. Reducing the variation in treatment is likely to lead to lower costs and better outcomes.
@article{Stenson-2017-ID246,
  title     = {Management of acute asthma exacerbations},
  abstract  = {{PURPOSE} {OF} {REVIEW}: Herein, we review the current guidelines for the
               management of children with an acute asthma exacerbation. We focus on
               management in the emergency department, inpatient, and {ICU} settings.
               {RECENT} {FINDINGS}: The most recent statistics show that the prevalence of
               asthma during childhood has decreased in certain demographic subgroups and
               plateaued in other subgroups. However, acute asthma accounts for
               significant healthcare expenditures. Although there are few, if any, newer
               therapeutic agents available for management of acute asthma exacerbations,
               several reports leveraging quality improvement science have shown
               significant reductions in costs of care as well as improvements in outcome.
               {SUMMARY}: Asthma is one of the most common chronic conditions in children
               and the most common reason that children are admitted to the hospital.
               Nevertheless, the evidence to support specific agents in the management of
               acute asthma exacerbations is surprisingly limited. The management of acute
               exacerbations focuses on reversal of bronchospasm, correction of hypoxia,
               and prevention of relapse and recurrence. Second-tier and third-tier agents
               are infrequently used outside of the {ICU} setting. Reducing the variation
               in treatment is likely to lead to lower costs and better outcomes.},
  author    = {Stenson, Erin K. and Tchou, Michael J. and Wheeler, Derek S.},
  journal   = {Curr Opin Pediatr},
  volume    = {29},
  number    = {3},
  pages     = {305--310},
  year      = {2017},
  month     = {1},
  url       = {https://www.ncbi.nlm.nih.gov/pubmed/28306629},
  pmid      = {28306629},
  doi       = {10.1097/MOP.0000000000000480},
  file      = {FULLTEXT:pdfs/000/000/000000246.pdf:PDF}
}

Downloads: 0